Clifford, a veteran of three space shuttle missions with 665 hours in orbit as a Mission Specialist, on Wednesday will be honored at the AAN and AAN Base Annual Achieving Awards Luncheon, April 25, 2012, at the Ernest N. Morial Convention Middle in New Orleans. Related StoriesUCSF research on disposition disorders aims to progress understanding and treatment of depressionStudy displays post-stroke loss of speech could be recoveredEstrogen-like drug may not be good for women with Alzheimer's dementiaThe Open public Leadership in Neurology Award honors a person or group outside of the medical profession.Non-e of the 3 medicines has yet been approved for use in the United States, although daclatasvir is under review by the FDA currently. The researchers discovered that the combination cleared HCV in 93 percent of trial participants who had not been previously treated, along with in 87 percent of these with past failed treatments. However, the addition of a 4th medication, ribavirin, increased the get rid of rate of sufferers with past failed therapies to 93 percent, comparable to that of patients who were receiving treatment for the first time. The development of interferon-free treatments has been a tremendous step forward in the typical of care, said lead writer Andrew Muir, MD, MHS, in a press release. These medications are highly effective and well tolerated by individuals at all stages of liver disease.